For almost 50 years, Mr. Winston Ko, the Chairman and CEO of Genervon Biopharmaceuticals, has embraced entrepreneurial challenges as an investor and developer seeking to make a positive impact. Recognizing the lack of curative therapies for patients suffering from CNS diseases, Mr. Ko commissioned a team of scientists to find a novel endogenous embryonic stage regulator of the human nervous system. His team discovered this critical regulator, and Mr. Ko founded Genervon Biopharmaceuticals to develop a small peptide and active analog of this master regulator for the treatment of neurodegenerative diseases and disorders using a multi-target approach.
Winston Ko, MBA CEO, Chairman of the Board
Dorothy Ko, MS Chief Operating Officer
Raymond Chau, Ph.D. Chief Scientist
Mark Kindy, Ph.D. Director of Scientific Research
Frank Young, M.D. Regulatory Advisor
PC Chan-Yu, Ph.D. Clinical Research
Tony Shum, M.D. Medical Director
Lorraine DeCesare, R.Ph. Clinical Trial Manager
In addition, expert consultants, specialists, and contract research organizations contribute to the ongoing success of Genervon's research and development. The company is dedicated to streamlining the drug development and clinical trial processes through the use of contract research organizations (CROs). This strategy offers the benefits of fast delivery, higher levels of efficiency, and lowered costs associated with drug development.